Efectividad de la radiofrecuencia pulsada sobre nervios periféricos en espasticidad focal severa refractaria: estudio observacional ambispectivo

IF 0.4 Q3 Medicine

Rehabilitacion Pub Date : 2025-09-27 DOI:10.1016/j.rh.2025.100939

S. Otero-Villaverde , M. Caparros-Calle , R. Martin-Mourelle , P. Vega-Gomez , A. Montoto-Marques , J. Formigo-Couceiro

{"title":"Efectividad de la radiofrecuencia pulsada sobre nervios periféricos en espasticidad focal severa refractaria: estudio observacional ambispectivo","authors":"S. Otero-Villaverde , M. Caparros-Calle , R. Martin-Mourelle , P. Vega-Gomez , A. Montoto-Marques , J. Formigo-Couceiro","doi":"10.1016/j.rh.2025.100939","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the efficacy and safety of pulsed radiofrequency (PRF) in spasticity.</div></div><div><h3>Design</h3><div>Ambispective observational study of patients with spasticity refractory to conventional treatment, enrolled from July/2019 to December/2024 and treated with PRF.</div></div><div><h3>Materials and methods</h3><div>The following scales were evaluated: Modified Ashworth (MAS), Visual Analogue (VAS) before, 2 and 6 months after the procedure, and GAS, PGA and PGI-C. The study was approved by the Galician Ethics Committee for Pharmaceutical Research (registration number 2023/153). All patients signed the informed consent form. We used the Wilcoxon test to analyse significant differences, concordance using Cohen's Kappa Coefficient for MAS and Intraclass Correlation Coefficient (ICC) for VAS.</div></div><div><h3>Results</h3><div>22 patients were included in the study. There were no significant differences between baseline MAS and at 2 months (p=0.096) and 6 months (p=0.257), nor between baseline VAS and at 2 months (p=0.109) and 6 months (p=0.102). Agreement was moderate between baseline and 2-month MAS (Kappa=0.549, p<0.001), good between baseline and 6-month MAS (Kappa=0.698, p<0.001), and excellent for both baseline and 2-month VAS (ICC=0.935, p<0.001) and 6-month VAS (ICC=0.975, p<0.001). The mean GAS, PGA and PGI-C at 6 months were -1.35, 0.1 and 0.05, respectively. No adverse events were observed.</div></div><div><h3>Conclusions</h3><div>(PRF) at 45V appears to be ineffective for the treatment of spasticity and related pain. Further research is warranted to confirm these findings.</div></div>","PeriodicalId":39532,"journal":{"name":"Rehabilitacion","volume":"59 4","pages":"Article 100939"},"PeriodicalIF":0.4000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rehabilitacion","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0048712025000593","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

To evaluate the efficacy and safety of pulsed radiofrequency (PRF) in spasticity.

Design

Ambispective observational study of patients with spasticity refractory to conventional treatment, enrolled from July/2019 to December/2024 and treated with PRF.

Materials and methods

The following scales were evaluated: Modified Ashworth (MAS), Visual Analogue (VAS) before, 2 and 6 months after the procedure, and GAS, PGA and PGI-C. The study was approved by the Galician Ethics Committee for Pharmaceutical Research (registration number 2023/153). All patients signed the informed consent form. We used the Wilcoxon test to analyse significant differences, concordance using Cohen's Kappa Coefficient for MAS and Intraclass Correlation Coefficient (ICC) for VAS.

Results

22 patients were included in the study. There were no significant differences between baseline MAS and at 2 months (p = 0.096) and 6 months (p = 0.257), nor between baseline VAS and at 2 months (p = 0.109) and 6 months (p = 0.102). Agreement was moderate between baseline and 2-month MAS (Kappa = 0.549, p< 0.001), good between baseline and 6-month MAS (Kappa = 0.698, p< 0.001), and excellent for both baseline and 2-month VAS (ICC = 0.935, p< 0.001) and 6-month VAS (ICC = 0.975, p< 0.001). The mean GAS, PGA and PGI-C at 6 months were -1.35, 0.1 and 0.05, respectively. No adverse events were observed.

Conclusions

(PRF) at 45 V appears to be ineffective for the treatment of spasticity and related pain. Further research is warranted to confirm these findings.

查看原文本刊更多论文

脉冲射频对周围神经在严重难治性局灶性痉挛中的作用：双翅目观察研究

目的评价脉冲射频（PRF）治疗痉挛的有效性和安全性。设计对2019年7月至2024年12月接受PRF治疗的难治性痉挛患者进行前瞻性观察研究。材料与方法对术前、术后2、6个月的改良Ashworth评分（MAS）、视觉模拟评分（VAS）及GAS、PGA、PGI-C进行评分。该研究已获得加利西亚药物研究伦理委员会（注册号2023/153）的批准。所有患者均签署了知情同意书。我们使用Wilcoxon检验分析显著性差异，使用Cohen’s Kappa系数分析MAS的一致性，使用class内相关系数（ICC）分析VAS的一致性。结果22例患者纳入研究。基线MAS与2个月（p = 0.096）和6个月（p = 0.257）之间无显著差异，基线VAS与2个月（p = 0.109）和6个月（p = 0.102）之间也无显著差异。基线和2个月MAS之间的一致性为中等（Kappa = 0.549, p< 0.001），基线和6个月MAS之间的一致性为良好（Kappa = 0.698, p< 0.001），基线和2个月VAS （ICC = 0.935, p< 0.001）和6个月VAS （ICC = 0.975, p< 0.001）均为优秀。6个月时GAS、PGA和PGI-C的平均值分别为-1.35、0.1和0.05。未观察到不良事件。结论：45v的PRF对痉挛及相关疼痛的治疗无效。需要进一步的研究来证实这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rehabilitacion Medicine-Rehabilitation

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： La revista que es desde hace más de 40 años la publicación oficial de la Sociedad Española de Rehabilitación y referente de la mayoría de las Sociedades de la Especialidad de los países americanos de habla hispana. Se publican 5 números pluritemáticos al año y uno monográfico sobre un tema del mayor interés y actualidad designado por el consejo de redacción.